ARCHIVE
LONDON
REGENERATIVE MEDICINE NETWORK
JUNE MEETING - Tuesday 13th June 2006
The next monthly meeting of the London Regenerative
Medicine Network will be held in the evening of Tuesday
13th June at King's College London, Guy's Hospital Campus
at London Bridge, London SE1 (Harris Lecture Theatre, Hodgkin
Building, Guy's Hospital Campus at London Bridge, London
SE1). The
meeting will focus on three key areas:
1] Tissue
engineering -
Professor Kevin Shakesheff (University of Nottingham +
RegenTec Ltd.)
2] The commercial
development of regenerative medicine - Dr. Paul Martin (Institute for the
Study of Genetics, Biorisks and Society - University of
Nottingham)
3] UK Stem Cell
Foundation and its first investments in clinical
trials - David
Macauley, Chief Executive, UK Stem Cell
Foundation
SPEAKERS
Prof. Kevin
Shakesheff -
University of Nottingham + RegenTec Ltd.
Kevin Shakesheff is Professor of Tissue Engineering and
Drug Delivery in the new Wolfson-funded Centre for
Regenerative Medicine at the University of Nottingham. He
has been involved in the launch of 2 spin-outs from the
University, Regentec Ltd. and Critical Pharmaceuticals
Ltd.
In the established field of protein therapeutics there is a
recognition of the importance of delivery systems to
enhance clinical efficacy. Kevin's talk will explore the
potential to enhance cell therapies by designing delivery
systems that maximise the effectiveness of stem cell doses.
Delivery systems can offer improved control of cell
location after adminstration, control of local
extracellular matrix and growth factor environments and a
strong intellectual property position in the late stages of
commercial development of a cell therapy. This talk will
explore the rationale for cell delivery systems, commercial
and clinical opportunities and some examples of delivery
systems in development.
Dr. Paul Martin
- Institute for the Study of Genetics,
Biorisks and Society - University of Nottingham
Dr. Paul Martin is Senior Lecturer and Deputy Director
of the Institute for the Study of Genetics, Biorisks
and Society (IGBiS) at the University of Nottingham. Paul
originally trained as a molecular biologist and
subsequently worked as a health policy analyst before
taking a PhD in science and technology studies at the
University of Sussex. His research interests cover
innovation in the biotechnology industry, the social and
ethical issues raised by genetics and the regulation of
new medical technologies. Paul's talk will focus on the
innovations that drove the business models for the
commercialisation of human haemopoetic stem cells in the
1980's + 1990's and contrast them to the position today
for human embryonic stem cells. Have we learnt our
lesson?
David Macauley
- Chief Executive -
UK Stem Cell
Foundation
In February 2005, a group of high profile scientists
and business people launched an initiative to establish
a £100 million foundation in the UK to support stem cell
research and its applications. The purpose of the
Foundation is to ensure a speedy transfer from the
laboratory bench to the bedside. To attain this goal,
the Foundation plans initially to directly fund
promising clinical projects in UK medical schools,
universities and hospitals. This will be achieved by
providing support to enable translational research
studies and clinical trials to advance; and by promoting
a collaborative dialogue amongst the stem cell research
community. The creation of the Foundation has been
personally endorsed by the Prime Minister and the
Chancellor of the Exchequer, as well as by the Royal
Society of Medicine, MRC and BBSRC, and by twenty
leading research universities, including Cambridge,
Imperial, Oxford and UCL.
David has very kindly agreed to bring us all up to date
with the Foundation's progress including news on the
Foundation's first funding ventures in stem cell clinical
trials.
To
researve a place, please just email the Network
Secretary: secretary@regenmednetwork.com
DETAILS
This meeting is free of charge to everyone through the
generous financial support of our principle
sponsors; GlaxoSmithKline and the Guy's, King's & St Thomas' Annual
Fund, plus
invaluable support from the Department of Biochemical
Engineering, UCL and the the Wolfson Centre for
Age-Related Diseases, KCL.
PLEASE NOTE THAT DUE TO LECTURE THEATRE SEATING CAPACITY +
CATERING ARRANGEMENTS, IF YOU WISH TO ATTEND THIS EVENT YOU
MUST REPLY AS REQUESTED, OTHERWISE UNFORTUNATELY YOU WILL
NOT BE ABLE TO GAIN ADMISSION. Seat allocation is on a
first come first served basis. If you wish to attend, all
that is required, is to email the Secretary -
secretary@regenmednetwork.com and type "Please add me to the guest
list - Thank you" or something similar!!!
AGENDA
18.00 - Registration over tea
and coffee
18.30 - Welcome - Dr. Chris Mason (UCL) - Co-organiser of
the Network
18.35 - "The
commercial development of regenerative
medicine" - Dr. Paul Martin -
Institute for the Study of Genetics, Biorisks and Society -
University of Nottingham
19.00 - Q+A Session
19.10 - "New
scaffolds and cell delivery systems"
- Prof. Kevin Shakesheff
- University of Nottingham + RegenTec
Ltd.
19.35 - Q+A Session
19.45 - "An update
on the UK Stem Cell Foundation" - David Macauley, Chief
Executuive, UK Stem Cell Foundation
20.00 - Closing remarks - Dr. Stephen Minger (King's) -
Co-organiser of the Network
20.10 - 22.00 - Networking reception - enjoy a glass of
wine or two in the Wolfson Centre for Age-Related Diseases,
KCL
Please only respond if you can definitely make the meeting.
Replies must go to - secretary@regenmednetwork.com
We look
forward to seeing everyone on Tuesday 13th
June!
Stephen Minger + Chris Mason
Co-organisers, London Regenerative Medicine Network.
www.regenmednetwork.com
PRINCIPLE
SPONSORS
Guy's, King's and St Thomas' Annual
Fund
London
Regenerative Medicine Network
"Bringing the regenerative medicine, stem cell and tissue
engineering community together..."